Akebia Therapeutics, Inc. AKBA

AKBA Company Overview

Akebia Therapeutics, Inc. is a U.S.-based biopharmaceutical company focused on the development and commercialization of therapies for patients with kidney disease. The company operates within the biotechnology and pharmaceuticals industries, with a primary emphasis on chronic kidney disease (CKD)–related conditions. Akebia’s core commercial product and principal revenue driver is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) approved in the U.S. for the treatment of anemia due to CKD in adults on dialysis.

Founded in 2007, Akebia initially pursued a broader pipeline targeting metabolic and kidney diseases, including rare disorders. Over time, the company narrowed its strategic focus to CKD anemia, culminating in the U.S. approval of vadadustat in 2024 for dialysis-dependent patients. Akebia’s evolution reflects a transition from a clinical-stage biotechnology company to a commercial-stage organization with a single primary marketed product.